Analyzing stem cells and using AI to improve glioblastoma treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on glioblastoma, specifically IDH-wildtype, by integrating multi-omics approaches with clinical data to identify immune markers that can predict patient prognosis. It aims to enhance understanding of glioblastoma through the study of stem cell cultures and their sensitivity to various chemotherapeutics. Additionally, the study seeks to establish ethical guidelines for the use of patient data in AI-assisted prediction systems, while also creating accessible information for patients to empower them in their treatment decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

To be enrolled in the study patients must:

1. Have a radiological diagnosis of supratentorial glioblastoma, or
2. Have a radiological diagnosis of first recurrence of a primary supratentorial glioblastoma (for which a formal histopathologic diagnosis of glioblastoma had made at first surgery), according with RANO criteria;
3. Be a candidate to neurosurgery for glioblastoma at the Operational Unit of Neurosurgery Fondazione Policlinico Gemelli IRCCS;
4. Be of an age of 18 years or above;
5. Provide written informed consent for participation to the study.

Exclusion criteria

To be enrolled in the study patients must not:

1. Have not enough pathological material removed at surgery available both for mandatory routine histopathological diagnosis and for the present study, as judged by the Principal Investigator;
2. Have not a definitive pathological diagnosis of a primary supratentorial glioblastoma, according with 2021 World Health Organization classification.

Where it's running

• Fondazione Policlinico Universitario A. Gemelli IRCCS
  Rome, Italy Recruiting

Study contacts

• Principal investigator: Quintino Giorgio D'Alessandris, MD, PhD — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Quintino Giorgio D'Alessandris, MD, PhD
• Email: quintinogiorgio.dalessandris@policlinicogemelli.it
• Phone: +39 06 30155414

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Temozolomide with or without WSD0922-FU for EGFR-Mutant, IDH-Wildtype Glioblastoma

  This trial tests whether adding WSD0922-FU to temozolomide helps slow disease progression in adults with EGFR-mutant, IDH-wildtype glioblastoma.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT07708961

• Retifanlimab With or Without DFMO for Progressive High-Grade Gliomas

  This trial tests whether retifanlimab, with or without DFMO, is safe and may help treat progressive high-grade gliomas in adults.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT07468136

• Temporally-Modulated Pulsed Radiation Therapy plus TMZ for MGMT-Unmethylated Glioblastoma

  This study tests whether temporally-modulated pulsed radiation therapy plus temozolomide improves outcomes for people with newly diagnosed MGMT-unmethylated, IDH-wildtype glioblastoma.

  Recruiting at 54 sites Phase 3 NRG Oncology · Irvine, California and 53 other locations · NCT07452458

• GI-102 With or Without Pembrolizumab Before Surgery for Recurrent or Progressive Grade 4 Gliomas

  The team will test whether giving GI-102 alone or together with pembrolizumab before surgery helps adults with recurrent or progressive IDH‑wildtype glioblastoma or IDH‑mutant grade 4 astrocytoma.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07301268

• 177Lu-PSMA-617 treatment for IDH‑wildtype gliomas

  This trial will test whether the radiopharmaceutical 177Lu-PSMA-617 is safe for adults with IDH‑wildtype gliomas who have completed standard surgery and radiation.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07223034

• Using a continuous glucose monitor to manage high blood sugar in glioblastoma

  We will try continuous glucose monitors to help adults with newly diagnosed glioblastoma control high blood sugar during treatment.

  Recruiting Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT07091864

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.